RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2007. Total product revenue increased 32% year-over-year to $67.4 million for the third quarter of 2007, compared to $51.2 million for the third quarter of 2006. Total product revenue for the first nine months of 2007 was $193.8 million, a year-over-year increase of 33%. COLAZAL® generated revenue of $31.1 million for the third quarter of 2007 compared to $27.0 million for the third quarter of 2006. COLAZAL generated revenue of $92.4 million for the first nine months of 2007 compared to $73.1 million for the first nine months of 2006. XIFAXAN® revenue for the third quarter of 2007 was $16.1 million, compared to $15.9 million for the third quarter of 2006. XIFAXAN revenue for the first nine months of 2007 increased 44% compared to the first nine months of 2006. MOVIPREP®, OSMOPREP™ and VISICOL®, which comprise our bowel cleansing product line, generated revenue of $12.1 million for the third quarter of 2007, compared to $6.6 million for the third quarter of 2006. Our bowel cleansing product line contributed $34.6 million in product revenue for the first nine months of 2007 compared to $34.0 million for the first nine months of 2006.
